To view this email as a web page, click here.
 
Blood pressure drug recalls soar
The recalls of a widely used hypertension drug due to carcinogenic impurities are expanding.
Read more
 
Rheumatoid arthritis drug poses fatal side effects
FDA is warning about an increased risk of death and blood clots in the lungs in patients with rheumatoid arthritis taking a specific dosage of tofacitinib (Xeljanz, Xeljanz XR).
Read more
 
The biggest obstacle to biosimilar cancer development
From our sister brand, Managed Healthcare Executive: Biosimilar drugs are poised to transform the cancer drug market, so why is uptake so slow?
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.